ATE440087T1 - 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen - Google Patents

2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen

Info

Publication number
ATE440087T1
ATE440087T1 AT04705675T AT04705675T ATE440087T1 AT E440087 T1 ATE440087 T1 AT E440087T1 AT 04705675 T AT04705675 T AT 04705675T AT 04705675 T AT04705675 T AT 04705675T AT E440087 T1 ATE440087 T1 AT E440087T1
Authority
AT
Austria
Prior art keywords
pkc
theta
inhibitors
compounds
diaminopyrimidene
Prior art date
Application number
AT04705675T
Other languages
English (en)
Inventor
Mario Cardozo
Derek Cogan
Charles Cywin
Georg Dahmann
Darren Disalvo
John Ginn
Anthony Prokopowicz
Denice SPERO
Erick Young
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of ATE440087T1 publication Critical patent/ATE440087T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00—Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/30—Coordination compounds
    • H10K85/351—Metal complexes comprising lanthanides or actinides, e.g. comprising europium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04705675T 2003-01-30 2004-01-27 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen ATE440087T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44370003P 2003-01-30 2003-01-30
PCT/US2004/002240 WO2004067516A1 (en) 2003-01-30 2004-01-27 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta

Publications (1)

Publication Number Publication Date
ATE440087T1 true ATE440087T1 (de) 2009-09-15

Family

ID=32825361

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04705675T ATE440087T1 (de) 2003-01-30 2004-01-27 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen

Country Status (7)

Country Link
US (2) US20040242613A1 (de)
EP (1) EP1590334B1 (de)
JP (1) JP2006515014A (de)
AT (1) ATE440087T1 (de)
CA (1) CA2514612A1 (de)
DE (1) DE602004022633D1 (de)
WO (1) WO2004067516A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1438053B1 (de) * 2001-10-17 2008-09-10 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
HRP20040887A2 (en) * 2002-03-26 2005-04-30 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
EP1539141B1 (de) * 2002-08-29 2010-07-14 Boehringer Ingelheim Pharmaceuticals Inc. 3-(sulfonamidoethyl)-indol-derivate zur verwendung als glucocorticoid-mimetika bei der behandlung von entzündlichen, allergischen und proliferativen erkrankungen
DE602004022633D1 (de) 2003-01-30 2009-10-01 Boehringer Ingelheim Pharma 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
JP4886511B2 (ja) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
UY28526A1 (es) * 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
CA2541059C (en) * 2003-10-03 2013-09-17 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescent probes for use in protein kinase inhibitor binding assay
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP4970048B2 (ja) 2003-12-22 2012-07-04 カトリーケ・ウニフェルジテイト・ルーベン・カー・イュー・ルーベン・アール・アンド・ディ イミダゾ［４，５−ｃ］ピリジン化合物および抗ウイルス治療の方法
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
US7582631B2 (en) * 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7795272B2 (en) * 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
RU2373197C2 (ru) * 2004-03-30 2009-11-20 Тайсо Фармасьютикал Ко., Лтд. Пиримидиновые производные, обладающие активностью в отношении мсн
EP1763524A1 (de) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Indolderivate und deren verwendung als kinaseinhibitoren
CA2571937A1 (en) * 2004-07-08 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of pkc-theta
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
DE602005013580D1 (de) 2004-12-21 2009-05-07 Leuven K U Res & Dev Imidazoä4,5-cüpyridinverbindung und verfahren zur antiviralen behandlung
EP1836166B1 (de) * 2004-12-27 2009-06-17 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid-mimetika, verfahren zu deren herstellung, pharmazeutische zusammensetzungen und deren verwendung
KR100917511B1 (ko) 2005-02-28 2009-09-16 니뽄 다바코 산교 가부시키가이샤 Ｓｙｋ 저해 활성을 갖는 신규한 아미노피리딘 화합물
US7468382B2 (en) * 2005-03-28 2008-12-23 Boehringer Ingelheim International Gmbh Pyridine derivatives useful as inhibitors of PKC-theta
EA015890B1 (ru) 2005-06-14 2011-12-30 Тайджен Байотекнолоджи Ко. Лтд. Производные пиримидина
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007072158A2 (en) * 2005-12-21 2007-06-28 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2007076247A1 (en) * 2005-12-21 2007-07-05 Boehringer Ingelheim International Gmbh Pyrimidine derivatives useful as inhibitors of pkc-theta
TWI360549B (en) 2006-07-07 2012-03-21 Gilead Sciences Inc Novel pyridazine compound and use thereof
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
EP2223925A1 (de) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase-Inhibitoren
WO2008070507A2 (en) * 2006-12-06 2008-06-12 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20080242861A1 (en) * 2007-04-02 2008-10-02 Chi-Feng Yen Synthesis of amino-protected cyclohexane-1,4-diyldimethanamine and its derivatives
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
AU2008275918B2 (en) 2007-07-17 2014-01-30 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as PKC inhibitors
CA2704266A1 (en) * 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
DK2268635T3 (en) 2008-04-21 2015-09-14 Taigen Biotechnology Co Ltd Heterocyclic Compounds
SI2300472T1 (sl) * 2008-06-06 2012-05-31 Boehringer Ingelheim Int Glukokortikoidni mimetiki postopki za njihovo pripravo farmacevtski sestavki in njihove uporabe
BRPI0918472A2 (pt) 2008-09-01 2015-12-01 Astellas Pharma Inc composto 2,4-diaminopirimidina
TW201021855A (en) 2008-11-13 2010-06-16 Taigen Biotechnology Co Ltd Lyophilization formulation
EA201101568A1 (ru) * 2009-04-28 2012-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta
JP2012148977A (ja) * 2009-05-20 2012-08-09 Astellas Pharma Inc アミノシクロヘキシルアルキル基を有する２，４−ジアミノピリミジン化合物
US20110142814A1 (en) * 2009-12-16 2011-06-16 New York University Methods for Using Protein Kinase C-Theta Inhibitors in Adoptive Immunotherapy
HUE029196T2 (en) 2010-06-04 2017-02-28 Hoffmann La Roche Aminoprimidine derivatives as LRRK2 modulators
SG189043A1 (en) 2010-11-10 2013-05-31 Hoffmann La Roche Pyrazole aminopyrimidine derivatives as lrrk2 modulators
MX343653B (es) 2010-12-17 2016-11-07 Rhodes Tech Síntesis de clorhidrato de metilfenidato a baja temperatura.
AU2012245387C1 (en) * 2011-04-22 2016-05-05 Signal Pharmaceuticals, Llc Substituted Diaminocarboxamide and Diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
AU2016244228B2 (en) * 2011-04-22 2019-02-21 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
GB201108225D0 (en) 2011-05-17 2011-06-29 Amakem Nv Novel KBC inhibitors
LT2864291T (lt) 2012-06-26 2017-01-10 Bayer Pharma Aktiengesellschaft N-[4-(chinolin-4-iloksi)cikloheksil(metil)](hetero)arilkarboksamidai kaip androgeno receptoriaus antagonistai, jų gamyba ir panaudojimas kaip medicininių produktų
CA2923765C (en) 2013-09-18 2021-06-29 University Of Canberra Stem cell modulation ii
RU2016129380A (ru) 2013-12-20 2018-01-25 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Замещенные диаминопиримидильные соединения, их композиции и способы лечения с их участием
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
AU2015309686B2 (en) 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
WO2016100308A1 (en) 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-jun n-terminal kinase in skin
ES2877642T3 (es) 2014-12-16 2021-11-17 Signal Pharm Llc Formulaciones de 2-(terc-butilamino)-4-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-pirimidin-5-carboxamida
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
EP3795553B1 (de) 2015-07-24 2024-05-15 Celgene Corporation Verfahren zur synthese von (1r,2r,5r)-5-amino-2-methylcyclohexanolhydrochlorid und nützliche zwischenprodukte darin
US10336734B2 (en) 2015-08-02 2019-07-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors of ACK1/TNK2 tyrosine kinase
CA3093189A1 (en) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
WO2020234103A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft Identification and use of kras inhibitors
EP4628488A4 (de) * 2022-12-16 2026-01-21 Adlai Nortye Biopharma Co Ltd Cyclin-k-degrader und verwendung davon

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
DE69839735D1 (de) * 1997-12-15 2008-08-28 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
US6797706B1 (en) 1999-06-09 2004-09-28 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclecarboxamide derivative
DE60006541D1 (de) 1999-06-30 2003-12-18 Merck & Co Inc Src-kinase hemmende verbindungen
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
MEP13408A (en) 2001-05-29 2010-06-10 Bayer Schering Pharma Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
EP1438053B1 (de) * 2001-10-17 2008-09-10 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2489458A1 (en) 2002-06-14 2003-12-24 Altana Pharma Ag Substituted diaminopyrimidines
DE602004022633D1 (de) 2003-01-30 2009-10-01 Boehringer Ingelheim Pharma 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen

Also Published As

Publication number Publication date
US20050124640A1 (en) 2005-06-09
EP1590334A1 (de) 2005-11-02
EP1590334B1 (de) 2009-08-19
WO2004067516A1 (en) 2004-08-12
CA2514612A1 (en) 2004-08-12
US7550473B2 (en) 2009-06-23
US20040242613A1 (en) 2004-12-02
DE602004022633D1 (de) 2009-10-01
JP2006515014A (ja) 2006-05-18

Similar Documents

Publication Publication Date Title
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
NO20030895D0 (no) Ny anvendelse av dipeptidyl peptidase IV inhibitorer
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
IS7925A (is) Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
NO20083411L (no) Indaneddiksyrederivater og deres anvendelse som farmasoytiske midler, intermediater og fremgangsmater for fremstilling
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
NO20021358L (no) Alkylendiamin-substituerte heterocykler
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
DE602004030222D1 (de) 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen
NO20060230L (no) Nye aminobenzofenonforbindelser
EA200601239A1 (ru) Замещённые хинолиновые соединения
ATE432260T1 (de) Pyridinderivate als pkc-theta-hemmer
NO20073839L (no) Kinolinderivat, fremgangsmate for fremstilling og anvendelse av dette, og legemiddel inneholdende dette
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
DE60308699D1 (en) 2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
ES2333026T3 (es) Derivados de ciclohexil-1,4-diamina sustituidos.
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
ATE383343T1 (de) Imidazolderivate verwendbar als histamin h3 rezeptorliganden
EP1597234A4 (de) Neue verbindungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties